Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1994-11-17
1997-05-27
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Lymphokine
424 852, 424 854, 514 21, A61K 3819, A61K 4505
Patent
active
056329830
ABSTRACT:
A method of treating cellular immune deficiency in a patient including the steps of determining the presence of a cellular immune deficiency and co-administering to the patient an effective amount of a thymic peptide combined with an effective amount of an immunomodulating natural nonrecombinant cytokine preparation.
REFERENCES:
patent: 4116951 (1978-09-01), Wang
patent: 4353821 (1982-10-01), Birr et al.
patent: 4466918 (1984-08-01), Birr et al.
patent: 4470926 (1984-09-01), Birr et al.
patent: 4612365 (1986-09-01), Birr et al.
patent: 4659694 (1987-04-01), Horecker
patent: 4716148 (1987-12-01), Horecker
patent: 4910296 (1990-03-01), Birr et al.
patent: 5093114 (1992-03-01), Rideout et al.
patent: 5114711 (1992-05-01), Bell et al.
The Investigator's Handbook provided by the Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, p. 22.
Belldegrun and Rosenberg, "Adoptive immunotherapy of urologic tumors", Cancer Treat. Res. 46:213-233, 1989.
Borden, "Interferons: rationale for clinical trials in neoplastic disease", Ann. Int. Med. 91:492-479, 1979.
Chang and Rosenberg, "Overview of interleukin-2 as immunotherapeutic agent", Semin. Surg. Oncol. 5(6):385-390, 1989.
Chirigos and Talmadge, "Immunotherapeutic agents: their role in cellular immunity and their therapeutic potential" Springer Seminars in Immunopathol. 8:327-336, 1985.
Cortesina et al., "Treatment of recurrent squamous cancer cell of head and neck with low doses of interleukin 2 injected . . . " Br. J. Cancer 62:2482-2485, 1988.
Cortesina et al., "Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low . . . " Br. J. Cancer 69:572-576, 1994.
DeSimone et al., "Report of the symposium on the use of intravenous gammaglobulin (IVIG) in adults infected with HIV" J. Clin. Lab. Anal. 4:313-317, 1990.
Devos, Nucleic Acids Res., 11:4307-4323, 1983.
Frillingos et al., "Appearance of thymosin .alpha. in supernatants of monocytes . . . " Archives of Biochemistry and Biophysics, vol. 296, No. 1, Jul., pp. 356-363, 1992.
Goldstein et al., Proc. Natl. Acad. Sci., 74(2):725-729, Feb. 1977.
Goldstein and Laslo, "The role of interferon in cancer therapy: a current perspective" Ca-A Cancer Journal for Clinicians 38:258-290, 1988.
Goldstein, in Combination Therapies 2, pp. 39-48, Plenum Press, NY, 1993.
Hadden et al., "Strategies of immune reconstitituion: effects of lymphokines . . . " Life Sci. 44:V-XII, 1989.
Hadden et al., "The characterization of immunotherapeutic agents" Immunopheron Reviews 1:1-64, 1992.
Hadden, "Immunotherapy of human immunodeficiency virus infection" TIPS Reviews, 1991.
Hadden, "Thymic Endocrinology" Int. J. Immunopharmacol. 14:345-352, 1992.
Hadden and Smith, "Immunopharmacology" JAMA, 268:2964-2969, 1992.
Hadden et al., Cell. Immunol. 144:228-236, 1992.
Hadden "Immunostimulants" Immunology Today 276, vol. 14, No. 6, 1993.
Hadden et al., Arch. Otolaryngol. 120:395-403, 1994a.
Hwu and Rosenberg, "The genetic modification of T cells for cancer therapy: an overview . . . " Cancer Detect. Prev. 18(1):43-50, 1994b.
IGIV News Update, "An extra measure of viral safety", vol. 1, No. 2, Dec. 1993.
Kameda et al., "Mixed lymphokines in low does prolong life in cyclophosphamide-treated melanoma-bearing mice" Int. J. Immunother. 8:1-5, 1992.
Lane and Fauci, "Therapeutic approaches to the underlying immune deficit in AIDS" Abstracts Int. Conf. on AIDS, Paris, 1986.
Maric et al., "Immunostimulatory activity of prothymosin-alpha in senescence" Annals New York Academy of Science, pp. 148-158.
Mattijssen, "Clinical and immunopathological results of a phase II study . . . " J. Immunother. 10:63-68, 1991.
Merigan, "Combination anti HIV therapy in combinaton therapy 2" eds. Garaci and Goldstein, Plenum Press, pp. 225-229, 1993.
Mishell and Shiigi, Selected Methods in Cellular Immunology, Freeman, pp. 23-24, 1981.
Morgan et al., "Selective in vitro Growth of T lymphocytes from normal human bone marrows" Science 193:1007-8, 1976.
Mule and Rosenberg, "Mechanistic aspects of successful immunotherapy . . . " Prog. Clin. Biol., 244:79-91, 1987.
Mutch and Hutson, "Levamisole in the adjuvant treatment of colon cancer", Clin. Pharmacol. 10:95-109, 1991.
Paetkeau et al., J. Immunol. 117:1320-4, 1976.
Pulley et al., "Intravenous, intralesional and endolymphatic adminstration of lymphokines in human cancer" Lymphokine Research, vol. 5, Supp. 1, pp. S157-163, 1986.
Rosenberg, et al., "Observations on the systemic adminstration of autologous lymphokine-activated killer cells and recombinant . . . " New. Eng. J. Med. 313:1485-1492, 1985.
Rosenberg et al., "A progress report on the treatment of 157 patients with advanced cancer . . . " N. Engl. J. Med. 316:889-897, 1987.
Rosenberg, "Immunotherapy of cancer by systemic adminstration of lymphoid cells plus interleukin-2" J. Biol. Resp. Mod. 3:501-511, 1994.
Shuloff, "Thymic peptide hormones: basic properties and clinical applications in cancer" CRC Critical Reviews in Oncology/Hematology, 3:3309-276, 1985.
Spreafico, "Use of levamisole in cancer patients" Drugs 19:105-116, 1980.
Symoens and Rosenthal, "Levamisole in the modulation of immune response: the current experimental and clinical state" J. Reticuloendothel. Soc. 21:175-219, 1977.
Talmadge et al., "Screening for biological response modifiers: methods and rationale" Martinus Nijhoff, Boston, pp. 121-129 and pp. 181-182, 1985.
Tanigushi et al., "Structure and expression of a cloned cDNA for human interleukin-2" Nature, 302:305-310, 1983.
Webb et al., "Mitogen-induced human lymphocyte activation in serum-free medium" Clinical Immunology and Immunopathology, 1:304-310, 1973.
Kovacs et al., "Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 . . . " New Eng. J. Med. 332:567-575, 1995.
Achutamurthy Ponnathapura
University of South Florida
LandOfFree
Method for treating secondary immunodeficiency does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating secondary immunodeficiency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating secondary immunodeficiency will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2327167